

---

---

**S.B. 86 - Amendments to Preferred Drug List**

**Fiscal Note**

2009 General Session  
State of Utah

---

---

**State Impact**

Enactment of this bill will result in savings in FY 2010 of \$240,000 General Fund and \$600,300 Federal Funds (\$840,300 total). Additionally there are ongoing savings in FY 2011 of \$362,500 General Fund and \$906,800 Federal Funds (\$1,269,300 total).

	<u>2009</u> <u>Approp.</u>	<u>2010</u> <u>Approp.</u>	<u>2011</u> <u>Approp.</u>	<u>2009</u> <u>Revenue</u>	<u>2010</u> <u>Revenue</u>	<u>2011</u> <u>Revenue</u>
General Fund	\$0	(\$362,500)	(\$362,500)	\$0	\$0	\$0
General Fund, One-Time	\$0	\$122,500	\$0	\$0	\$0	\$0
Federal Funds	\$0	(\$600,300)	(\$906,800)	\$0	\$0	\$0
<b>Total</b>	<b>\$0</b>	<b>(\$840,300)</b>	<b>(\$1,269,300)</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

---

---

**Individual, Business and/or Local Impact**

Enactment of this bill likely will not result in direct, measurable costs and/or benefits for individuals or local governments. The savings listed above come through payments for generic drugs rather than brand name drugs. Those businesses providing the generic drugs would see increased revenues while businesses providing brand name drugs would see a decrease in revenues.